BCAB - Bioatla Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-46.08M

Cash

192.7M

Avg Qtr Burn

-21.98M

Short % of Float

8.20%

Insider Ownership

14.08%

Institutional Own.

71.38%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
mecbotamab vedotin (BA3011) (anti-AXL ADC) Details Solid tumor/s, Soft tissue sarcoma, Non-small cell lung carcinoma, Bone sarcoma, Cancer	Phase 2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ozuriftamab vedotin (BA3021) (ROR2-ADC) Details Solid tumor/s, Ovarian cancer, Non-small cell lung carcinoma, Melanoma, Eye disease , Leber congenital amaurosis, Cancer	Phase 2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BA3071 (CAB anti-CTLA-4 antibody) Details Solid tumor/s, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.